HIV patients are known to have up to a two-fold increase in heart-related events, compared with the general population. Could treatment with statins reduce this risk?
Dr. Steven Fine, an infectious disease specialist affiliated with the University of Rochester, reviews the recently published results of the REPRIEVE trial. The big picture is a 35% reduction in heart-related events. Dr. Fine digs into the details and statistics of the trial, and the encouraging results of statin treatment, even in those deemed to be at lower risk. Related Content:
HIV Prevention Research in the Kink-Involved Population
Doxy-PEP Part II: Where Are We Now?
Tackling Stigma with Compassion: Harm Reduction in Clinical Practice
RSV Vaccination in HIV Positive Adults
We can do it! Improving access to care for transgender and gender diverse patients
What is Doxy-PEP? A Conversation about the Use of Doxycycline Post Exposure Prophylaxis to Prevent STIs
Safe and Safer Supply for People Who Use Drugs
Making a SPLASH! Long-acting Injectables for vulnerable populations with HIV
Tackling Syphilis: A Conversation with the New York State Department of Health AIDS Institute Office of Sexual Health and Epidemiology
Integrating Hepatitis C Treatment into Opioid Treatment Programs: The Greenwich House Story
Talking to patients about Lenacapavir (Sunlenca); the new long-acting injectable medication for HIV
Providing Affirming Care to Transgender Youth
The Resurgence of Congenital Syphilis in NYS: A Look at the Past and Present to Change the Future
What We Know About Xylazine
START Trial Update
How Can We Destigmatize HIV and Pregnancy?
Taking the Next Step: Providing Proactive Reproductive Health Care in Your Clinical Setting
Universal Hepatitis C Screening among Pregnant Persons: The Time is Now
Some Basics About HIV-Hepatitis B Co-Infection
Create your
podcast in
minutes
It is Free
» Divine Intervention Podcasts
Real English Conversations Podcast - Learn to Speak & Understand Real English with Confidence!
To Die For SPY by Aliia Roza
EconTalk
煽风点火